Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Jennifer Hsieh is active.

Publication


Featured researches published by Jennifer Hsieh.


Contraception | 2014

Efficacy and safety of an ascending-dose, extended-regimen levonorgestrel/ethinyl estradiol combined oral contraceptive

David Portman; Andrew M. Kaunitz; Brandon Howard; Herman Weiss; Jennifer Hsieh; Nancy Ricciotti

OBJECTIVE To evaluate the efficacy and safety of an ascending-dose, extended-regimen (ADER) combined oral contraceptive consisting of levonorgestrel (LNG) 150 mcg/ethinyl estradiol (EE) 20 mcg for 42 days, LNG 150 mcg/EE 25 mcg for 21 days, LNG 150 mcg/EE 30 mcg for 21 days and EE 10 mcg for 7 days. STUDY DESIGN This was a multicenter, open-label, phase 3, single-arm study. Sexually active women aged 18-40 years were enrolled and received ADER for up to 1 year (4 consecutive 91-day cycles). Participants kept diaries to record adherence, bleeding/spotting and other contraceptive use. Efficacy was measured using the Pearl Index and the life-table method; safety and tolerability were assessed through reported adverse events (AEs). RESULTS A total of 3701 women were enrolled and 2144 completed the study. The Pearl Index was 3.19 [95% confidence interval (CI), 2.49-4.03], based on 70 pregnancies that occurred after ADER initiation and ≤ 7 days after the last LNG/EE or EE-only pill in women aged 18-35 years, excluding cycles in which another contraceptive method was used. Life-table pregnancy rate was 2.82% (95% CI, 2.23%-3.57%) for all users aged 18-35 years. Unscheduled bleeding/spotting decreased with increasing EE doses within each cycle and decreased after cycle 1. No unexpected AEs or changes in laboratory parameters were reported. CONCLUSION This study demonstrated that ADER effectively prevented pregnancy with a favorable safety and tolerability profile.


Contraception | 2015

Ovulatory effects of three oral contraceptive regimens: a randomized, open-label, descriptive trial.

Larry Seidman; Robin Kroll; Brandon Howard; Nancy Ricciotti; Jennifer Hsieh; Herman Weiss

OBJECTIVE This study describes ovarian activity suppression of a 21/7-active low-dose combined oral contraceptive (COC) regimen that included only ethinyl estradiol (EE) during the traditional hormone-free interval (HFI) and two commercially available 28-day regimens, a 24/4 and a 21/7 regimen. STUDY DESIGN The randomized, open-label, parallel-group descriptive study was conducted at two US sites. Healthy, reproductive-aged women (n=146) were randomized to one of three groups for three consecutive 28-day cycles, as follows: treatment 1 (n=39 completed): 21/7-active COC [21 days of 150 mcg desogestrel (DSG)/20 mcg EE, followed by 7 days of 10 mcg EE (DSG/EE+7 days EE)], treatment 2 (n=39 completed): 24 days of 3mg drospirenone (DRSP)/20 mcg EE, followed by 4 placebo (PBO)-pill days (DRSP/EE+4 days PBO) and treatment 3 (n=42 completed): 21 days of 100 mcg levonorgestrel (LNG)/20 mcg EE, followed by 7 PBO-pill days (LNG/EE+7 days PBO). The primary outcome was ovarian activity suppression assessed by transvaginal ultrasound and serum hormone concentrations and classified using the Hoogland and Skouby (H/S) method. RESULTS Ovarian activity rate (H/S grade 4 or 5) was low for all three treatments: 0% [95% confidence interval (CI) 0-2.8] for DSG/EE+7 days EE, 1% (95% CI 0.2-5.2) for DRSP/EE+4days PBO and 1% (95% CI 0-3.9) for LNG/EE+7 days PBO. All three treatments showed similar suppression of serum progesterone, 17β-estradiol, follicle-stimulating hormone and luteinizing hormone levels. CONCLUSIONS The 21/7-active low-dose COC regimen (DSG/EE+7 days EE) showed ovarian activity suppression that was similar to the 24/4 (DRSP/EE+4 days PBO) and 21/7 (LNG/EE+7days PBO) regimens. IMPLICATIONS The 21/7-active low-dose COC regimen (DSG/EE+7 days EE) that included only EE during the traditional HFI showed suppression of ovarian follicular activity that was similar to the 24/4 (DRSP/EE+4days PBO) and the 21/7 (LNG/EE+7 days PBO) comparator regimens.


Reproductive Sciences | 2014

A Comparison of the Pharmacokinetic Profile of an Ascending-Dose Extended-Regimen Combined Oral Contraceptive to Those of Other Extended Regimens.

Mona Darwish; Mary Bond; Nancy Ricciotti; Jennifer Hsieh; Jill Fiedler-Kelly; Thaddeus H. Grasela

Quartette (levonorgestrel [LNG]/ethinyl estradiol [EE] and EE) is an ascending-dose, extended-regimen combined oral contraceptive (COC) that consists of a constant dose of LNG 150 µg on days 1 to 84 with EE 20 µg on days 1 to 42, 25 µg on days 43 to 63, 30 µg on days 64 to 84, and 10 µg of EE monotherapy on days 85 to 91. A population pharmacokinetic (PK) model for EE was developed using nonlinear mixed-effects modeling to characterize the PK profile of EE administered in Quartette and other extended-regimen LNG/EE COCs. Model-predicted plasma concentration–time profiles demonstrated a stepwise increase in systemic exposure to EE during the first 84 days of the cycle following each EE dose change. Lower concentrations of EE were noted during the final 7-day period of EE 10 µg. Gradual increases in EE seen with Quartette may decrease the incidence of unscheduled bleeding frequently observed during early cycles of extended-regimen COCs.


Contraception | 2016

Efficacy and safety of a 21/7-active combined oral contraceptive with continuous low-dose ethinyl estradiol

Robin Kroll; Ronald Ackerman; Robert Feldman; Brandon Howard; Herman Weiss; Jennifer Hsieh; Nancy Ricciotti

OBJECTIVE Substituting low-dose ethinyl estradiol (EE) for the hormone-free interval in combined oral contraceptives (COCs) may enhance ovarian suppression and improve tolerability. This noncomparative phase 3 study evaluated the efficacy and safety of a 21/7-active COC regimen including 21days of desogestrel (DSG)/EE followed by 7days of EE. STUDY DESIGN This multicenter, open-label, phase 3, single-arm study enrolled sexually active women aged 18-40years at risk for pregnancy. Women received up to 1year, or 13 consecutive 28-day cycles, of DSG 150mcg/EE 20mcg for 21days and EE 10mcg alone for 7days. Participants kept diaries to record compliance, bleeding/spotting and other contraceptive use. Efficacy was measured using the Pearl Index (PI) and life-table approach. Safety and tolerability were assessed primarily through reported adverse events (AEs). RESULTS A total of 2858 women enrolled and 1680 completed the study. Forty-six pregnancies in 2401 women aged 18-35years occurred after COC initiation and up to 7days after last DSG/EE or EE-only tablet was taken. When cycles in which another contraceptive method was used were excluded, the PI was 2.68 [95% confidence interval (CI), 1.96-3.57]. The cumulative pregnancy rate after 1year of treatment was 2.47% (95% CI, 1.85-3.29) for all users aged 18-35years. When only cycles during which women considered compliant were included, the PI was 2.00 (95% CI, 1.39-2.80). AEs were similar to those seen with other oral contraceptives. CONCLUSIONS This 21/7-active DSG/EE COC with 7days of low-dose EE was efficacious and well tolerated for pregnancy prevention. IMPLICATIONS STATEMENT This phase 3 open-label study demonstrated that a 21/7-active COC regimen including 21days of DSG 150mcg/EE 20mcg and 7days of EE 10mcg was efficacious and well tolerated for pregnancy prevention.


Obstetrics & Gynecology | 2014

Phase 3 study of desogestrel and ethinyl estradiol combined oral contraceptive for pregnancy prevention.

Robin Kroll; Brandon Howard; Jennifer Hsieh; Nancy Ricciotti

INTRODUCTION: Substituting low-dose ethinyl estradiol for the typical hormone-free interval in combined oral contraceptives may enhance ovarian suppression and improve tolerability. This phase 3 study evaluated the efficacy and safety of a 28-day combined oral contraceptive regimen including 21 days of desogestrel and ethinyl estradiol followed by 7 days of ethinyl estradiol. METHODS: This was a multicenter, open-label, phase 3, single-arm study that enrolled sexually active women 18–40 years old at risk for pregnancy. Women received up to 1 year, or 13 consecutive 28-day cycles, of 150 micrograms desogestrel and 20 micrograms ethinyl estradiol for 21 days and 10 micrograms ethinyl estradiol alone for 7 days. Patients kept diaries to record compliance, bleeding or spotting, and other contraceptive use. Efficacy was measured using the Pearl Index and life table approach. Safety and tolerability were assessed through reported adverse events. RESULTS: A total of 2,858 women were enrolled and 1,680 completed the study. Forty-six pregnancies in 2,401 women aged 18–35 years occurred after combined oral contraception initiation and up to 7 days after the last desogestrel and ethinyl estradiol or ethinyl estradiol-only tablet was taken. When cycles in which another birth control method was used were excluded, the Pearl Index was 2.68 (95% confidence interval [CI] 1.96–3.57). The life table pregnancy rate was 2.47% (95% CI 1.85%–3.29%) for all users aged 18–35 years. When only cycles during which women considered compliant were included, the Pearl Index was 2.00 (95% CI 1.39–2.80). Adverse events were similar to those seen with other oral contraceptives. CONCLUSIONS: This 28-day desogestrel and ethinyl estradiol combined oral contraceptive, including 7 days of low-dose ethinyl estradiol, was efficacious and well tolerated for pregnancy prevention.


Journal of Pediatric and Adolescent Gynecology | 2016

Effect of Extended 30 μg Ethinyl Estradiol with Continuous Low-Dose Ethinyl Estradiol and Cyclic 20 μg Ethinyl Estradiol Oral Contraception on Adolescent Bone Density: A Randomized Trial.

Janet Gersten; Jennifer Hsieh; Herman Weiss; Nancy Ricciotti


Journal of Pediatric and Adolescent Gynecology | 2016

Sexual and Contraceptive Behaviors among Adolescents Requesting Emergency Contraception

Carrie Cwiak; Brandon Howard; Jennifer Hsieh; Nancy Ricciotti; Gina Sucato


Obstetrics & Gynecology | 2014

Single-Dose 1.5 mg Levonorgestrel Emergency Contraceptive Safety in Young Women (Various Age Groups).

Gina Sucato; Herman Weiss; Nancy Ricciotti; Jennifer Hsieh


Archive | 2014

Original research article Efficacy and safety of an ascending-dose, extended-regimen levonorgestrel/ethinyl estradiol combined oral contraceptive ☆,☆☆,☆☆☆,☆☆☆☆,★,★★,★★★

David Portman; Andrew M. Kaunitz; Brandon Howard; Herman Weiss; Jennifer Hsieh; Nancy Ricciotti


Journal of Pediatric and Adolescent Gynecology | 2014

Reasons for Requesting Emergency Contraceptive Pills Among Adolescents in a Study Simulating Over-the-Counter Access

A. Rometo; Gina Sucato; B. Howard; Nancy Ricciotti; Jennifer Hsieh

Collaboration


Dive into the Jennifer Hsieh's collaboration.

Top Co-Authors

Avatar

Brandon Howard

University of Pennsylvania

View shared research outputs
Top Co-Authors

Avatar

Herman Weiss

Albert Einstein College of Medicine

View shared research outputs
Top Co-Authors

Avatar

Gina Sucato

Boston Children's Hospital

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

A. Rometo

Boston Children's Hospital

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge